Vaxcyte, Inc. (PCVX)
NEUTRAL基本面
37
价格
$62.05
市值
$9.16B
第一部分 · 这家公司值多少
概览
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
0
截至2025/12/31的财政年度
净利润
$-767M
截至2025/12/31的财政年度
自由现金流
$-669M
股东权益合计
$2.69B
负债合计
$317M
流动比率
5.72
利息覆盖率
-
债务/EBITDA
-
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$109.00
当前价格
$62.05
安全边际
+43.1%
公允价值区间
$103.55 - $114.45
估算方法
估值指标
市盈率（P/E）
-
ROE
-28.5%
市净率（P/B）
3.34
P/FCF
-
毛利率
-
ROIC
-32.1%
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
-32.1%
WACC
11.2%
ROIC − WACC
-43.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
基本面分析标准
通过（6）
- EPS shows upward trend
- Price CAGR 15.36%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 88% Buy
未通过（9）
- ROIC -32.1%
- P/B Ratio 3.34
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -37.6%
- Earnings Surprise avg -14.9%
- Share Dilution 11.5%
- Piotroski F-Score 1/9
不可用（12）
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-评分
存在严重财务隐患
盈利质量
低质量：需深入审查会计处理
股权稀释
正在发行新股，稀释所有权
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Grant E. Pickering M.B.A. | Co-Founder, CEO & Director | 57 |
| Mr. Andrew L. Guggenhime M.B.A. | President & CFO | 57 |
| Mr. James T. Wassil M.B.A., M.S. | Executive VP & COO | 56 |
| Mr. Mikhail Eydelman J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 43 |
| Mr. Harp Dhaliwal M.B.A. | Chief Technical Operations Officer | 52 |
| Dr. Jeff Fairman Ph.D. | Co-Founder & VP of Research | 61 |
| Ms. Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | 52 |
| Mr. Jeff Macdonald | Executive Director of Investor Relations | - |
| Ms. Whitney Jones | Chief People Officer | - |
| Ms. Janet Graesser | Senior Vice President of Corporate Affairs | - |
审计风险
3
董事会风险
6
薪酬风险
8
股东权利风险
8
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for PCVX, sourced from Markets Gazette.